Pub. Date : 2021 Nov
PMID : 33574568
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice. | sl010110 | sirtuin 2 | Mus musculus |
| 2 | SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation. | sl010110 | sirtuin 2 | Mus musculus |
| 3 | These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation. | sl010110 | sirtuin 2 | Mus musculus |
| 4 | In type 2 diabetic ob/ob mice, single oral dose of SL010110 (100 mg/kg) suppressed gluconeogenesis accompanied by the suppressed hepatic SIRT2 activity, increased p300 activity, enhanced PEPCK1 acetylation and degradation. | sl010110 | sirtuin 2 | Mus musculus |
| 5 | This study reveals that SL010110 is a lead compound with a distinct mechanism of suppressing gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and potent anti-hyperglycemic activity for the treatment of T2D. | sl010110 | sirtuin 2 | Mus musculus |